Pyrotinib versus placebo in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic breast cancer Post date 31 October 2023 ← Caring for the whole person: the consultant neurologist → Row over ultra-processed foods panel highlights conflicts of interest issue at heart of UK science reporting